Abstract: The present invention relates to methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease (CD AD). In particular, the invention relates to antibodies that bind to C. difficile antigens and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile associated disease, shedding of C. difficile, and C. difficile associated mortality. The compositions of the present application comprise: mammalian or avian antibodies which bind to a C. difficile Toxin B; and mammalian or avian antibodies that bind to a C. difficile vegetative cell antigen and/or a C. difficile endospore antigen.

Abstract: The present invention relates to methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease (CD AD). In particular, the invention relates to antibodies that bind to C. difficile antigens and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile associated disease, shedding of C. difficile, and C. difficile associated mortality. The compositions of the present application comprise: mammalian or avian antibodies which bind to a C. difficile Toxin B; and mammalian or avian antibodies that bind to a C. difficile vegetative cell antigen and/or a C. difficile endospore antigen.

Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease.

Abstract: The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which bind a least one Influenza A antigen selected from the group consisting of H1, H3 and H5, the immune material being derived from hyperimmune milk products such as hyperimmune colostrum said hyperimmune milk products being prepared by inoculation of mammals with antigen composed of a least one Influenza A antigen selected from H1, H3 and H5.